As for DKD, the tetracycline antibiotic minocycline showed potential for treatment benefit in rodent DR, mainly by downregulating the ROS/TXNIP/NLRP3 inflammasome pathway [126]. This evidence concerns the gene NLRP3 and diabetic kidney disease.